CXCL1 and breast carcinoma: Moreover, the exogenous addition of CXCL1‐overexpressing EV‐Apo (EV‐AporCXCL1, 200 μg/20 g, q3d) strongly reversed the synergistic inhibition effect between BHS and paclitaxel on breast cancer growth and lung metastasis.